摘要
A recent study published in Nature by Dominik Pfister et al.1 unveiled a darker side of immune checkpoint blockade(ICB)immunotherapy in the context of nonalcoholic steatohepatitis-associated hepatocellular carcinoma(NASH-HCC),whereby anti-PD1 treatment paradoxically accelerates hepatocarcinogenesis.
基金
This work was supported by the National Key R&D Program of China(No.2020YFA0509200/2020YFA0509203)
RGC-CRF Hong Kong(C4041-17GF
C7026-18G)
RGC Theme-based Res Scheme Hong Kong(T12-703/19-R).
